Glucose Control and Cardiovascular Outcomes in Individuals with Diabetes Mellitus: Lessons Learned from the Megatrials

Heart Failure Clinics

Volumn 8, Issue 4, 2012, Pages 513-522

  Avitabile, Nicholas A ^a   Banka, Ajaz ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Glycemic control

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; GLICLAZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; UNITED KINGDOM;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INCIDENCE; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84866609768     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.06.009     Document Type: Review

References (33)

1. Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 2011, US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta (GA).
2. The Diabetes Control and Complications Trial Research Group (DCCT) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986.
3. UK Prospective Diabetes Study (UKPDS) Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
4. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. The Action to Control Cardiovascular Risk in Diabetes Study Group.
5. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE Collaborative Group.
6. Duckworth W.C., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
7. Kelly T.N., Bazzano L.A., Fonseca V.A., et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394-403.
8. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
9. Desouza C., Raghavan V.A., Fonseca V.A. The enigma of glucose and cardiovascular disease. Heart 2010, 96:649-651.
10. Myint P.H., Sinha S., Wareham N.J., et al. Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk Prospective Population Study. Stroke 2007, 38:271-275.
11. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000, 321(7258):405-412.
12. Nathan D.M., Cleary P.A., Backlund J.Y., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
13. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
14. Calles-Escandón J., Lovato L.C., Simons-Morton D.G., et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics. Diabetes Care 2010, 33(4):721-727.
15. Riddle M.C., Ambrosius W.T., Brillon D.J., et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010, 33(5):983-990.
16. Gerstein H.C., Pogue J., Mann J.F., et al. The relationship between dysglycemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005, 48:1749-1755. [abstract].
17. Bonds D.E., Miller M.E., Bergenstal R.M., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of The ACCORD study. BMJ 2010, 340:b4909.
18. Adler G.K., Bonyhay I., Failing H., et al. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009, 58:360-366.
19. Desouza C., Salazar H., Cheong B., et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003, 26:1485-1489.
20. Landstedt-Hallin L., Englund A., Adamson U., et al. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999, 246:299-307.
21. Fonseca V.A. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am J Cardiol 2011, 108(Suppl 3):52B-58B.
22. Woodward M., Patel A., Zoungas S., et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world?. Diabetes Care 2011, 34(12):2491-2495.
23. Agarwal L., Azad N., Emamele N., et al. Observations on renal outcomes in VADT. Diabetes Care 2011, 34(9):2090-2094.
24. Reaven P., Moritz T., Schwenke D., et al. Intensive glucose lowering therapy reduces cardiovascular disease events in Veterans Affairs trial participants with lower calcified coronary atherosclerosis. Diabetes 2009 Nov, 58(11):2642-2648.
25. Duckworth W.C. VA diabetes trial (VADT) update. 69th scientific sessions June 9, 2009, American Diabetes Association; Abstract 468-P. Presented.
26. Goldin A., Beckman J., Schmidt A., et al. Advanced glycation end products: sparking the development of vascular injury. Circulation 2006, 114(6):597-605.
27. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 2009, 52:1219-1226.
28. Ceriello A. Hypothesis: the "metabolic memory", the new challenge of diabetes. Diabetes Res Clin Pract 2009, 86(Suppl 1):S2-S6.
29. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
30. Erdmann E., Charbonnel B., Wilcox R.G., et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive Study (PROactive 08). Diabetes Care 2007, 30:2773-2778.
31. Horwich T.B., Fonarow G.C. Glucose, obesity, metabolic syndrome, and diabetes: relevance to incidence of heart failure. J Am Coll Cardiol 2010, 55(4):283-293.
32. Mannucci E., Monami M., Lamanna C., et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009, 19:604-612.
33. Turnbull F.M., Abraira C., Anderson R.J., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.